A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Identificadores
Identificadores
Fecha de publicación
2012Título de revista
ARTHRITIS AND RHEUMATISM
Tipo de contenido
Artigo